Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Lancet Neurol ; 23(5): 534-544, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38631769

RESUMEN

Progressive multifocal leukoencephalopathy is a rare but devastating demyelinating disease caused by the JC virus (JCV), for which no therapeutics are approved. To make progress towards addressing this unmet medical need, innovations in clinical trial design are needed. Quantitative JCV DNA in CSF has the potential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and treatment response in clinical trials to expedite therapeutic development, as do neuroimaging and other fluid biomarkers such as neurofilament light chain. Specifically, JCV DNA in CSF could be used in clinical trials as an entry criterion, stratification factor, or predictor of clinical outcomes. Insights from the investigation of candidate biomarkers for progressive multifocal leukoencephalopathy might inform approaches to biomarker development for other rare diseases.


Asunto(s)
Virus JC , Leucoencefalopatía Multifocal Progresiva , Humanos , Biomarcadores , Variaciones en el Número de Copia de ADN , ADN Viral/genética , Ensayos Clínicos como Asunto
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda